Reviews Supplements Carl Zeiss Meditec September 2013 : Page 1
OCT in Today’s Optometric Practice: Practice Management Pearls Part three of a three-part series on the important role of the CIRRUS HD-OCT and how it may ultimately allow practitioners to provide a higher standard of care to their patients. Welcome to part three of three in our series on the use of optical coherence tomography (OCT) in the modern optometric practice. Parts one and two provided highlights from a roundtable on OCT at this year’s SECO International meeting in Atlanta, which focused on how ZEISS’s CIRRUS HD-OCT offers robust and comprehensive clinical applications for glaucoma and retina disease management. The expert panel consisted of I. Ben Gaddie, OD, Diana L. Shechtman, OD, and Kirk L. Smick, OD, and in this, the ﬁ nal part of the series, the illustri-ous group takes on practice management topics related to the use of OCT (e.g., billing, paying for the instrument, utilizing OCT to build an optometric practice). Dr. Shechtman served as our retina expert, and Dr. Gaddie as our glaucoma guru, but here, we look to the wisdom of Dr. Smick. We hope you ﬁ nd the following information as useful as we ﬁ nd the CIRRUS HD-OCT. — Mark T. Dunbar, OD, Moderator Mark T. Dunbar, OD: As we become a more medical profession, and as the demand for eye care grows, it is incumbent on optometry to embrace and really utilize technology. ZEISS has led the way as far as opti-cal coherence tomography (OCT) software, advancing the technology more than any other spectral-domain OCT (SD-OCT) company. Kirk L. Smick, OD: I couldn’t agree more. In the next decade, optometrists as primary eye-care practitioners are going to be called upon to do more di-agnostic work in terms of eye disease. It behooves us to take advantage of the technology that’s out there. CIR-RUS HD-OCT is not a luxury piece of equipment; it’s an instrument we all Moderator really should have. Diana L. Shechtman, OD: While I never think that any diagnostic modality takes the place of my clini-cal skills, CIRRUS HD-OCT does give me more conﬁ dence in understand-ing the disease process and in diagnosing and manag-ing patients. Dr. Dunbar: Let’s revisit the role of the CIRRUS HD-OCT in today’s retina practice from a practice man-agement perspective. “ It behooves us to take advantage of the technology that’s out there. CIRRUS HD-OCT is not a luxury piece of equipment; it’s an instrument we all really should have. ” CIRRUS IN THE RETINA PRACTICE Dr. Dunbar: One of the main advantages of CIRRUS HD-OCT Mark T. Dunbar, OD, serves as the Director of Optometric Services and the Optometric Residency Supervisor at the University of Miami’s Bascom Palmer Eye Institute. He has authored numerous papers and is the writer for Review of Optometry’s monthly column “Retina Quiz.” I. Ben Gaddie, OD , is the immediate Past President of the Kentucky Optometric Association and President of the Optometric Glaucoma Society. He is the CEO of Gaddie Eye Centers in Louisville, Ky. Diana L. Shechtman, OD, is an Associate Professor of Optometry at Nova Southeastern University College of Optometry, where she serves as an attending optometric physician at the eye institute and diabetic/macula clinic. Kirk L. Smick, OD , is Chief of Optometry Services at Clayton Eye Center and an owner of the facility. He is also Chairman of the Continuing Education Committee for the International Vision Expo Meetings. is Advanced RPE Analysis, which quantiﬁ es RPE elevation and sub-RPE illumination and gives you change over time. It gives you the ability to quantitatively follow patients with age-related macular degeneration (AMD) to reafﬁ rm that there isn’t any ﬂ uid and that the patient hasn’t converted. It has been really astounding how far OCT technology has come in terms of following progression and pick-ing up on subtle cases. I. Ben Gaddie, OD: We see a lot of diabetic patients in my practice, and thanks to the CIRRUS HD-OCT, we can detect macular edema as well as any progression. We are also able to follow AMD patients in our ofﬁ ce to see the resolution of that edema, enabling us to take care of these patients and minimize their need to travel to see another eye-care provider. Dr. Shechtman: Regardless of what stage you can ﬁ nd clinically signiﬁ cant Sponsored by REVIEW OF OPTOMETRY SEPTEMBER 2013 1 The opinions expressed in this supplement to Review of Optometry ® do not necessarily reﬂ ect the views, or imply endorsement of, Carl Zeiss Meditec, Inc. They are the opinions of the panelists.